Cenobamate - YKP3089 - XCOPRI
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 01/03/2020
Pipeline Type
Newly Marketed
Phase Of Development
Phase 3
Sponsors and Collaborators
SK Life Sciences, Inc
Mechanism of Action
Ion Channel
Mechanism Description
Blocks sodium channels form being inactivated
Populations Tested In
Drug-resistant focal seizures
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD 2019
Location of Clinical Trials
Over 119 Clinical Sites, click on clinical trials link to learn more.
Clinical Trial link